ArticleiScience2025
Cell-based immune anticipation of the omicron variant in SARS-CoV-2 triple-vaccinated cancer patients.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 infections affect healthcare systems worldwide. Patients with cancer, a particularly vulnerable group, and oncology care takers were offered early access to mRNA-based vaccinations. We report the dynamics of humoral and cellular immune response parameters of 74 patients with cancer and 12 control participants after two basal vaccinations and a booster six months later. Upon booster vaccination, 78% of patients with tumor under active therapy (versus 50.8% prior to the boost) exhibited humoral and cellular spike protein responses, as compared to 100% and 73.3%, respectively, in those without active therapy. Conducted prior to the emergence of the Omicron variant of concern, we found Wuhan-Hu-1 spike-encoding mRNA vaccination to evoke T cell responses against peptides outside and within the Omicron-mutated region of the spike protein. The vast majority of patients with cancer achieved significant antibody titers upon repeated vaccinations. Accordingly, patients with tumor appeared well-protected, indicated by asymptomatic or mild breakthrough infections during the Omicron wave.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.